Comparative evaluation of efficacy of Trayodashang Guggul versus Rasona Pinda as an adjuvant with Katibasti in the management of Grudhrasi (Sciatica):  A randomized controlled trial [version 2; peer review: 2 approved with reservations]

• Published in: F1000 research Vol. 13; p. 9
• Main Authors: Rai, Mayank, Misar, Sadhana, Gamne, Reeya
• Format: Journal Article
• Language: English
• Published: 2024
• Subjects: Rasonapinda; katibasti; katipradesh; dashmool taila; trayodashang guggul; Grudhrasi; Ruka; Sciatica
• ISSN: 2046-1402; 2046-1402
• DOI: 10.12688/f1000research.139568.2

Background In ayurveda, sciatica can be correlated to ' Grudhrasi' under Vata Nanatmaja-Vyadhi (neurological disorders caused by Vata, one of the bodily humour). In this mainly bodily humours vata and kapha are vitiating producing symptoms like piercing pain, stiffness, twitching, numbness and pain radiating from lumbosacral region to lower limb up to the foot. Therapeutic plan includes stabilizing and bringing back the vitiated vata and kapha humours to equilibrium. The prevalence of sciatica varies considerably ranging from 3.8% in the working population to 7.9% in the nonworking population. Aim Comparative evaluation of efficacy of Rasonapinda and Trayodashang guggul as an adjuvant to katibasti (oil pooling therapy) in the management of Grudhrasi (Sciatica). Objectives To assess the efficacy of Rasonapinda as an adjuvant to katibasti in subjective and objective parameters of Grudhrasi (Sciatica). To assess the efficacy of Trayodashang guggul as an adjuvant to katibasti in subjective and objective parameters of Grudhrasi (Sciatica). To compare the efficacy of Rasonapinda and Trayodashang guggul as an adjuvant to katibasti in subjective and objective parameters. Standardisation of Rasonapinda (modified formvati). Methods In this study, a total of 60 patients will be enrolled and divided equally into two groups. In group A, Trayodashang Guggul 500 mg twice a day after meal with warm water for 30 days adjuvant with katibasti for the initial 7 days will be given. In group B, Rasonapinda 500 mg twice a day after meal with warm water adjuvant with katibasti for the initial 7 days will be given for 30 days. Result The result will be assessed on baseline of subjective and objective parameters and data will be compared after treatment. Conclusions It will be based on observations and results obtained. Trial registration CTRI No. - CTRI/2022/12/048534 Dated - 27/12/2022.